Top Markets
Coin of the day
Solasia Pharma K.K. Solasia Pharma K.K.

Solasia Pharma K.K.

4597
Rank in Stocks #24770
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Share Price
$0.20877985
Market Cap
$57.00M
Change (1 day)
-11.11%
Change (1 year)
-20.59%
Country
JP
Trade Solasia Pharma K.K. (4597)

Category

Stock price history for Solasia Pharma K.K. (4597)
Highest end of day price: $0.21 on 2026-08-01

Lowest end of day price: $2.17 on 2017-03-01
Stock price history of Solasia Pharma K.K. from 2017 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 1.92%
2025 -28.32%
2024 -29.74%
2023 6.85%
2022 -59.89%
2021 -29.23%
2020 -20.28%
2019 12.42%
2018 -61.95%
2017 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$171.67 -
DE
$163.45 27.37%
DE
$37.61 23.06%
JP
$222.98 32.09%
CH
$20.99 11.74%
IN